MTN 038
Status:Ongoing
Phase:I
Principal Investigator(s):
Objective:A Phase 1, Randomized, Pharmacokinetic and Safety Study of a 90 Day Intravaginal Ring Containing Tenofovir
Last updated May 3, 2021
Prevention Option(s):Microbicides
Study Design:Randomized
Arms and Assigned Interventions
DescriptionExperimental: Tenofovir (TFV) Intravaginal Ring (IVR)
The TFV IVR will be inserted during the enrollment visit (Day 0) and used continuously for approximately 91 days.
Drug: Tenofovir (TFV) IVR
Contains 1.4 g TFV
Mode of DeliveryRing
ARMsExperimental
Official Code:
NCT03670355
Trial Sponsors:
NIAID (DAIDS-ES: 38460)
Start Date
End Date
December 7, 2018
September 25, 2019
Enrollment:49
Age range:
18 Years ↔
45 Years
Population:Cisgender Women